• LAST PRICE
    5.9200
  • TODAY'S CHANGE (%)
    Trending Up0.0300 (0.5093%)
  • Bid / Lots
    5.0500/ 2
  • Ask / Lots
    6.3300/ 8
  • Open / Previous Close
    5.6400 / 5.8900
  • Day Range
    Low 5.6400
    High 5.9200
  • 52 Week Range
    Low 3.3500
    High 7.9300
  • Volume
    7,985
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Friday's close: 5.89
TimeVolumeNVNO
09:32 ET6315.64
09:33 ET3005.8065
09:35 ET4005.85
10:18 ET19955.9
11:38 ET7455.9
11:39 ET5485.91
01:38 ET2005.865
01:40 ET1005.85
01:44 ET1005.895
01:45 ET1005.88
02:00 ET1005.89
03:03 ET1785.91
03:15 ET7605.9141
03:24 ET5005.885
03:50 ET1005.92
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesNVNO
enVVeno Medical Corp
55.8M
-2.4x
---
United StatesHOWL
Werewolf Therapeutics Inc
56.0M
-0.8x
---
United StatesLTRN
Lantern Pharma Inc.
54.8M
-3.9x
---
United StatesCKPT
Checkpoint Therapeutics Inc
55.9M
-0.8x
---
United StatesMBIO
Mustang Bio Inc
54.7M
-0.6x
---
United StatesINZY
Inozyme Pharma Inc
57.4M
-0.6x
---
As of 2022-11-28

Company Information

enVVeno Medical Corporation is a med-tech company. The Company is focused on improving the standard of care in the treatment of venous disease. The Company is focused on developing tissue-based solutions that are designed for patients with chronic venous insufficiency (CVI). Its lead product, VenoValve, is a porcine based device being developed to surgically implanted in the deep venous system of the leg to treat severe CVI, including the potential to heal recurring venous leg ulcers. The VenoValve is designed to be implanted into the femoral vein of the patient in an open surgical procedure via a five-to-six-inch incision in the upper thigh. The VenoValve is being evaluated in the surgical anti-reflux venous valve endoprosthesis (SAVVE) United States clinical trial. In addition to the VenoValve, the Company is focused on the development of a second device, enVVe, for the treatment of venous disease.

Contact Information

Headquarters
70 DopplerIRVINE, CA, United States 92618-4306
Phone
949-261-2900
Fax
949-261-2992

Executives

Chief Executive Officer, Director
Robert Berman
Chief Financial Officer
Craig Glynn
Senior Vice President, Chief Medical Officer
Marc Glickman
Independent Director
Francis Duhay
Independent Director
Robert Gray

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$55.8M
Revenue (TTM)
$0.00
Shares Outstanding
9.5M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
1.28
EPS
$-2.45
Book Value
$5.74
P/E Ratio
-2.4x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.